SBA Member, 08.09.2017
Zurich, September 07, 2017. MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in South Korea. This expands the list of countries in which MetrioPharm has broad protection for MP1032 from Europe, the USA, Australia, New Zealand, Israel, China, Japan, Russia, and South Africa to South Korea.
The South Korean patent KR10-177011 was issued on August 21, 2017. Currently comprehensive patent protection exists for MP1032 in all major markets. In some countries, the parent application or divisional applications thereof are still pending.
“The granting of the South Korean patent is another success for our continuous patent work. South Korea plays an important part in our global strategy. With over 50 million inhabitants it represents a substantial market. In addition, the country has developed into an important pharmaceutical location in South-East Asia, over the last few years,” comments Dr. Wolfgang Brysch, CEO of MetrioPharm AG.
MP1032 is the lead compound of a class of proprietary immune modulators developed by MetrioPharm. MP1032 is believed to modulate the H2O2-mediated activation state of macrophages and downregulate the M1 state. In contrast to other immune-modulating and disease-modifying drugs, MP1032 does not impact T-cells and preferentially affects macrophages at the sites of inflammation. MP1032 has shown anti-inflammatory activity in animal models of disease and a favorable toxicology profile in pre-clinical studies.
MetrioPharm AG is a biotech company developing oral drug compounds for the treatment of autoimmune and other inflammatory diseases. MetrioPharm’s MP1000 pipeline consists of small molecule immune modulators for unmet medical needs in Immune-Mediated Inflammatory Diseases (IMIDs).
MetrioPharm AG was founded in 2007 and is headquartered in Zurich with research facilities in Berlin.